Previous studies have shown that treatment of patients with EGFR activating and sensitizing mutation-driven NSCLC with EGFR tyrosine kinase inhibitors (TKIs) achieved a response rate (RR) of 60–80% with a median progression-free survival (PFS) of 8–13 months [26–28]. Here, EGFR is linked to non-small cell lung carcinoma.